Tonix Pharmaceuticals Holding Corp.
TNXP
$17.82
$0.633.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.94% | 183.05% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.94% | 183.05% | -- | -- | -- |
| Cost of Revenue | 63.78% | 276.96% | -- | -- | -- |
| Gross Profit | -23.06% | 45.02% | -- | -- | -- |
| SG&A Expenses | 15.40% | 15.90% | 24.39% | 23.92% | 15.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.37% | -26.52% | -14.04% | -2.91% | 12.54% |
| Operating Income | 34.33% | 33.27% | 23.99% | 11.48% | -5.61% |
| Income Before Tax | -11.47% | -11.76% | -22.12% | 15.59% | -5.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.47% | -11.76% | -22.12% | 15.59% | -5.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.47% | -11.76% | -22.12% | 15.59% | -5.84% |
| EBIT | 34.33% | 33.27% | 23.99% | 11.48% | -5.61% |
| EBITDA | 34.86% | 34.54% | 25.79% | 13.63% | -2.93% |
| EPS Basic | -17.08% | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -17.08% | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 23,507.20% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |